Ginkgo Bioworks: Chief executive officer Jason R Kelly sold 45,682 shares

What happened

• Jason R Kelly, chief executive officer & founder, exercised or converted derivative awards on Oct 16, 2026 for 55,694 shares and 25,790 shares (two separate exercises) and sold 45,682 shares in an open-market sale on Oct 19, 2026 at $10.14 per share for $463,353.
• The filing shows the exercises/conversions on Oct 16, 2026 were recorded as derivative transactions (code M) and the Oct 19, 2026 sale was an open-market sale (code S).

Key details

• Transaction dates and prices: Oct 16, 2026 — exercised/converted derivatives for 55,694 and 25,790 shares (price N/A); Oct 19, 2026 — sold 45,682 shares at $10.14 per share for $463,353.
• Shares owned after the transaction: not stated in the filing.
• Relevant footnotes from the filing:
  • Each restricted stock unit (RSU) represents a contingent right to one share (F1).
  • The shares sold represent a sell-to-cover to satisfy tax withholding obligations in connection with vesting (F2).
  • The RSUs were approved by the compensation committee on Jul 28, 2026; one grant vested 75% on Oct 16, 2026 and 25% will vest on Jan 21, 2027 (F3).
  • Another RSU grant vests in equal quarterly installments over the next 12 quarters (F4).
• Filing timeliness: no late filing indication in the Form 4.

Why it may matter

• The filing shows RSUs vested and were converted to shares (derivative exercise), with a portion sold in the open market as a sell-to-cover transaction to satisfy tax withholding.
• The Form 4 does not show why the insider traded or why the company acted.